UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

     [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

                  For the quarterly period ended: September 30, 2003

                                       OR

    [_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

                        Commission file number: 000-9489


                               SWISS MEDICA, INC.
             (Exact name of registrant as specified in its charter)

              Delaware                        98-0355519
 (State or other jurisdiction of            (I.R.S. Employer
  Incorporation or organization)           Identification No.)


                          53 Yonge Street, Third Floor
                             Toronto, Canada M5E 1J3

                    (Address of principal executive offices)

                                  416-868-0202
               (Registrant's telephone number including area code)

                                Global Path Inc.
            5th Floor, 2 Toronto Street, Toronto, Ontario, Canada M5C
                        2B6 (Former name, former address
              and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days YES [X] NO [_]

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes [ ]No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: As of November 11, 2003 the issuer
had 24,109,843 shares of Common Stock, par value $0.001, issued and outstanding.


<PAGE>

Transitional Small Business Disclosure Format (Check one):    Yes [  ] No [X]


                           FORWARD-LOOKING STATEMENTS

    This report by Swiss Medica, Inc. (the "Company") contains forward-looking
statements. These are statements regarding financial and operating performance
and results and other statements that are not historical facts. The words
"expect," "project," "estimate," "believe," "anticipate," "intend," "plan,"
"forecast," and similar expressions are intended to identify forward-looking
statements. Certain important risks could cause results to differ materially
from those anticipated by some of the forward-looking statements. Some, but not
all, of the risks that could cause actual results to differ from those suggested
by the forward-looking statements include, among other things:

o    the loss of the services of any member of our management team and, in
     particular, the loss of the services of Raghu Kilambi, our Chairman and
     Chief Executive Officer, and Grant Johnson, our President and Chief
     Operating Officer;

o    our ability to continue to find and acquire bioscience products with
     demonstrated competitive advantages;

o    whether or not our products are able to compete successfully with
     bioscience products of other suppliers and whether or not some or all of
     our products are rendered obsolete by newer products;

o    our ability to successfully market the products we acquire;

o    the implementation of any government regulation that could make it more
     difficult or more costly to bring our products to market;

o    our ability to obtain financing as and when we need it; and other factors,
     all of which are difficult to predict and many of which are beyond our
     control.

    You are cautioned not to place undue reliance on these forward-looking
statements, which relate only to events as of the date on which the statements
are made. We undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the date hereof.
You should refer to and carefully review the information in future documents we
file with the Securities and Exchange Commission.


                               SWISS MEDICA, INC.
                           (Formerly Global Path Inc.)


<PAGE>

                                Table of Contents

PART I.  FINANCIAL INFORMATION

     Item 1.  Financial Statements

               Condensed Balance Sheet:                                       1
                  September 30, 2003

               Condensed Statements of Losses:                                2
              Three Months Ended September 30, 2003 and 2002 Nine Months
              Ended September 30, 2003 and 2002

               Condensed Statements of CashFlows:                             3
                 Nine Months Ended September 30, 2003 and 2002

              Notes to Condensed Financial Statements:                        4
               September 30, 2003

       Item 2.  Plan of Operation                                             7

       Item 3.  Controls and Procedures                                       7


PART II.  OTHER INFORMATION

       Item 1.  Legal Proceedings                                             9

       Item 2.  Changes in Securities                                         9

       Item 3.  Defaults Upon Senior Securities                               9

       Item 4.  Submission of Matters to a Vote of Security Holders           9

       Item 5.  Other Information                                            10

       Item 6.  Exhibits and Reports on Form 8-K                             10


<PAGE>

Item 1.  Financial Statements

                               SWISS MEDICA, INC.
                          (FORMERLY GLOBAL PATH, INC.)
                             CONDENSED BALANCE SHEET
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                   September 30, 2003  September 30, 2002
                                                   ------------------  ------------------
<S>                                                   <C>                 <C>
ASSETS

             Current Assets

Cash and cash equivalents                             $     59,279        $      1,749
Accounts Receivable                                   $      2,493        $         --
Inventory                                             $      8,110        $         --
Loan Receivable                                       $     30,000        $         --
Total Current Assets                                  $     99,882        $      1,749

             Other Assets

Security Deposits and Other Assets                    $     23,664        $     23,245
Property and Equipment (Note B):
Furniture and Equipment, at cost                      $     48,751        $         --
Less: Accumulated Depreciation                        $     (5,456)       $         --
                                                      ------------        ------------
                                                      $     43,295        $         --

Other Assets (Note B):
Royalty and Licences                                         7,500        $         --
Trade Marks                                                 45,000        $         --
Patents                                                    563,250        $         --
Copyrights                                                   1,500        $         --
Customer Lists                                              30,000        $         --
Non Compete                                                112,500        $         --
                                                      ------------        ------------
                                                      $    759,750        $         --
Less: Accumulated Depreciation                        $   (69,638)        $         --
                                                      ------------        ------------
                                                      $    690,112        $         --
                                                      $    856,953        $     24,994

LIABILITIES ANDSTOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts Payable and accrued expenses                 $    123,656        $    178,322
Due to shareholders                                   $         --        $    674,719
Other Advances                                        $    108,000        $         --

            Total Current Liabilities                 $    231,656        $    853,041

Commitments and Contingencies                         $         --        $         --

            STOCKHOLDER'S EQUITY

Preferred stock, par value $.001 per share;
  10,000,000 shares authorized; none issued
  at September 30, 2003                               $         --

Class A Common stock, par value $.001 per share;
  100,000,000 shares authorized; 22,844,649 shares
  issued and outstanding at September 30, 2003        $     22,845        $     23,126

Class B Common stock, par value $.001 per share;
  50,000,000 shares  authorized; 2,000,000 shares
  issued and outstanding at September 30, 2003        $      2,000        $         --

Additional paid-in-capital                            $ 16,190,227        $  3,951,421

Accumulated deficit                                   $(15,589,775)       $ (4,802,594)
                                                      ------------        ------------
Total stockholders' equity                            $    625,297        $   (828,047)
                                                      ------------        ------------
                                                      $    856,953        $     24,994
</TABLE>



                                       2
<PAGE>


<TABLE>
<CAPTION>
                                                             3 months ended                 9 months ended
                                                              September 30                   September 30
                                                          2003            2002            2003            2002
                                                      ------------    ------------    ------------    ------------
<S>                                                   <C>             <C>             <C>             <C>
Revenues from operations:                             $      2,788    $         --    $      2,788    $         --

Total Revenues:                                       $      2,788    $         --    $      2,788    $         --

Costs of Sales:
Total Cost of Sales                                   $      2,191    $         --    $      2,191    $         --

Gross Profit:                                         $        597    $         --    $        597    $         --
                                                      ------------    ------------    ------------    ------------
Costs and Expenses:
Research and Development - Stock Based                $         --    $         --    $  3,724,125    $         --
Selling, General and Administrative                   $    148,217    $    225,079    $    272,773    $  1,357,394
Selling, General and Admin.- Stock Based              $    252,156    $         --    $  6,361,149    $         --
Amortization and Depreciation                         $     46,425    $         --    $     75,094    $         --
Interest                                                              $     13,737                    $     22,880
                                                      ------------    ------------    ------------    ------------
Total Operating Expenses                              $    446,798    $    238,816    $ 10,433,141    $  1,380,274

Loss From Operations:                                 ($   446,201)   ($   238,816)   ($10,432,544)   ($ 1,380,274)

Other Income                                          $         --    $      3,432    $         --    $      6,991
Interest (Expense)                                    $         --    $         --    $         --    $         --
Provision for Income Tax:                             $         --    $         --    $         --    $         --
                                                      ------------    ------------    ------------    ------------

Net Loss                                              ($   446,201)   ($   235,384)   ($10,432,544)   ($ 1,373,283)
Loss Per Common Share (Basic and Assuming Dilution)   ($      0.02)   ($      0.01)   ($      0.45)   ($      0.06)
Weighted Average Common Shares Outstanding              22,088,037      22,517,585      11,561,414      21,699,976
</TABLE>



                                       3

<PAGE>


<TABLE>
<CAPTION>
                                                                    For the nine months   For the nine months
                                                                    ended September 30    ended September 30
                                                                           2003                  2002
                                                                           ----                  ----
<S>                                                                    <C>                   <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss from development stage operations                             $(10,432,544)         $ (1,373,283)
operations to cash used for operating activities:
Common stock issued in exchange for services rendered                  $  6,361,149          $    853,386
Common stock issued in exchange for expenses paid by shareholders      $     23,731
Common stock issued in exchange for acquired  research and
development costs                                                      $  3,724,125
Depreciation and amortization                                          $     75,094
Changes in assets and liabilities:
Accounts Receivable                                                    $     (2,493)
Inventory                                                              $     (8,110)
Prepaid expenses and deposits                                          $     (7,873)         $       (290)
Cash disbursed in excess of available fund                             $     (4,914)
Increase (decrease) in accounts payable and accrued expenses           $    (83,741)         $     (6,067)

NET CASH (USED IN) OPERATING ACTIVITIES                                $   (350,662)         $   (531,168)
CASH FLOWS FROM INVESTING ACTIVITIES:
Issuance of loan receivable                                            $    (30,000)

NET CASH (USED IN) INVESTING ACTIVITIES                                $    (30,000)

CASH FLOWS FROM FINANCING ACTIVITIES:
Other advances                                                         $    120,500
Proceeds from (repayments to) Other advances                           $    (12,500)
Proceeds from sale of common stock, net of costs                       $    321,131
Unrealized loss on Exchange Revaluation                                $     (8,246)
Proceeds from (repayments to) related parties advances, net            $     18,958          $    532,917

NET CASH PROVIDED BY FINANCING ACTIVITIES                              $    439,843          $    551,522

NET INCREASE IN CASH AND EQUIVALENTS                                   $     59,181          $      1,749
Cash and cash equivalents at the beginning of the period               $         98          $         --
Cash and cash equivalents at the end of the period                     $     59,279          $      1,749
Supplemental Disclosures of Cash Flow Information
Cash paid during the period for interest
Income taxes paid
Common stock issued for services                                       $  6,361,149          $    853,386
Common stock issued in exchange for debt                               $    766,796
Common stock issued in exchange for research and development costs     $  3,724,125
Common stock issued in exchange for expenses paid by shareholders      $     23,731
Common stock issued in exchange for office equipment                   $     48,751
Common stock issued in exchange for intangible assets                  $    759,750
</TABLE>

See accompanying footnotes to the unaudited condensed financial information



                                       3

<PAGE>


                               SWISS MEDICA, INC.
                      (FORMERLY GLOBAL PATH INCORPORATED)
                    NOTES TO CONDENSED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2003
                                  (UNAUDITED)


NOTE A - SUMMARY OF ACCOUNTING POLICIES

General

The accompanying unaudited condensed financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of
America for interim financial information and with the instructions to Form
10-QSB. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements.

In the opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included. The
results from developmental stage operations for the nine month period ended
September 30, 2003 are not necessarily indicative of the results that may be
expected for the year ended December 31, 2003. The unaudited financial
statements should be read in conjunction with the consolidated December 31, 2002
financial statements and footnotes thereto included in the Company's SEC Form
10-KSB.

Business and Basis of Presentation

Swiss Medica,Inc., formerly Global Path Incorporated (the "Company") was
reincorporated under the laws of the State of Delaware in September 2001. The
Company is currently a bioscience distribution Company.

Reclassification

Certain reclassifications have been made to conform to prior periods' data to
the current presentation. These reclassifications had no effect on reported
losses.

Stock Based Compensation

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure-an amendment of SFAS 123." This statement
amends SFAS No. 123, "Accounting for Stock-Based Compensation," to provide
alternative methods of transition for a voluntary change to the fair value based
method of accounting for stock-based employee compensation. In addition, this
statement amends the disclosure requirements of SFAS No. 123 to require
prominent disclosures in both annual and interim financial statements about the
method of accounting for stock-based employee compensation and the effect of the
method used on reported results. The Company has chosen to continue to account
for stock-based compensation using the intrinsic value method prescribed in APB
Opinion No. 25 and related interpretations.
Accordingly, compensation expense for stock options is measured as the excess,
if any, of the fair market value of the Company's stock at the date of the grant
over the exercise price of the related option. The Company has adopted the
annual disclosure provisions of SFAS No. 148 in its financial reports for the
year ended December 31, 2002 and for the quarter ended September 30, 2003. The
Company has no stock based awards of compensation issued and outstanding as of
September 30, 2003.



                                       4

<PAGE>


                               SWISS MEDICA, INC.
                      (FORMERLY GLOBAL PATH INCORPORATED)
                    NOTES TO CONDENSED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2003
                                  (UNAUDITED)


NOTE A - SUMMARY OF ACCOUNTING POLICIES (Continued)

New Accounting Pronouncements

In April 2003, the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 149, AMENDMENT OF STATEMENT 133 ON DERIVATIVE INSTRUMENTS AND HEDGING
ACTIVITIES. SFAS 149 amends SFAS No. 133 to provide clarification on the
financial accounting and reporting of derivative instruments and hedging
activities and requires that contracts with similar characteristics be accounted
for on a comparable basis. The provisions of SFAS 149 are effective for
contracts entered into or modified after September 30, 2003, and for hedging
relationships designated after June 30, 2003. The adoption of SFAS 149 will not
have a material impact on the Company's results of operations or financial
position.

In May 2003, the FASB issued SFAS No. 150, ACCOUNTING FOR CERTAIN FINANCIAL
INSTRUMENTS WITH CHARACTERISTICS OF BOTH LIABILITIES AND EQUITY. SFAS 150
establishes standards on the classification and measurement of certain financial
instruments with characteristics of both liabilities and equity. The provisions
of SFAS 150 are effective for financial instruments entered into or modified
after May 31, 2003 and to all other instruments that exist as of the beginning
of the first interim financial reporting period beginning after June 15, 2003.
The adoption of SFAS 150 will not have a material impact on the Company's
results of operations or financial position.

NOTE B - ACQUISITIONS

On May 20, 2003 the Company acquired nine patented bioscience products and
related intangible assets from General Cosmetics Corporation.

In consideration for the acquisition of the intangible assets, the Company
issued a total of 6,750,000 shares of restricted common stock. The stock that
was issued in this transaction was valued at 85 percent of its average closing
price ten days prior to and after May 21, 2003. In accordance with Accounting
Principles Board No. 29, Accounting for Non Monetary Transactions, the cost of
the intangible assets acquired is the fair value of the Company's common stock
issued of $4,532,625.

The cost to acquire the intangible assets has been preliminarily allocated to
the assets acquired according to estimated fair values and is subject to
adjustment when additional information concerning asset valuations are
finalized.

In connection with the acquisition of the intangible assets, the Company
acquired $3,724,125 of research and development assets which were written off
during the period ended June 30, 2003 and are included in the accompanying
statement of losses as research and development expenditures.

The Company has adopted SFAS No. 142, Goodwill and Other Intangible Assets,
whereby the Company periodically tests its intangible assets for impairment. On
an annual basis, and when there is reason to suspect that their values have been
diminished or impaired, these assets will be tested for impairment, and
write-downs to be included in results from operations may be necessary.



                                       5

<PAGE>


                               SWISS MEDICA, INC.
                      (FORMERLY GLOBAL PATH INCORPORATED)
                    NOTES TO CONDENSED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 2003
                                  (UNAUDITED)


NOTE B - ACQUISITIONS (Continued)

The intangible assets acquired are:

<TABLE>
<CAPTION>
                                     Gross                                           Weighted Average
                                   Carrying    Accumulated                Residual     Amortization
                                    Amount    Amortization      Net        Value      Period (Years)
                                   --------    --------      --------     ------     ----------------
<S>                                <C>          <C>           <C>          <C>             <C>
Amortizable Intangible Assets:
Patents                            $563,250     $(42,244)     $521,006     $   --          5.0
Customer Mailing Lists               30,000       (2,250)       27,750         --          5.0
Trademarks                           45,000       (3,375)       41,625         --          5.0
Non-compete agreements              112,500      (21,094)       91,406         --          2.0
Other                                 9,000         (675)        8,325         --          5.0
                                   --------     ---------     --------     ------
 Total                             $759,750     $(69,638)     $690,112         --          4.6
                                   --------     ---------     --------     ------
</TABLE>

Total amortization expense charged to operations for the nine months ended
September 30, 2003 was $69,638.

Estimated amortization expense for the years ended December 31:

       2003                             $ 116,042
       2004                               185,700
       2005                               150,544
       2006                               129,450
       2007                               129,450
       2008                                48,564
                                        ---------
       Total                            $ 759,750
                                        =========



                                       6
<PAGE>


PART 1 - ITEM 2 PLAN OF OPERATION

The following discussion and analysis is qualified by, and should be read in
conjunction with, our unaudited interim condensed consolidated financial
statements and the notes thereto included in Item 1 of this Quarterly Report on
Form 10-Q.

Prior to May 16, 2003 we were a holding company focused on acquiring, expanding
and developing technology companies and we had no operations.

As of May 16, 2003 we began to implement a new business plan pursuant to which
we will market and distribute bioscience health products. We retained a new
management team to implement this new business plan. Bioscience products are
natural compounds that have health promoting, disease preventing or medicinal
properties. We believe that consumers are deeply concerned about the management
and cost of their health care and the expensive, chemical-based prescription
drug approach predominant in modern medicine. We believe that this concern will
increase the demand for bioscience health products because natural products are
considered to be effective against many ailments and are more accessible than
prescription medications. The global market for herbal products is currently
estimated to be $62 billion and the World Health Organization has estimated that
the global market for herbal products will be worth $5 trillion dollars by the
year 2050.

On May 16, 2003 we acquired certain assets of General Cosmetics Corporation, a
Delaware corporation based in Munich, Germany. The acquisition was made by
issuing to General Cosmetics Corporation 6,750,000 shares of our restricted
Common Stock, subject to adjustment based on the terms of the March 31, 2003
definitive agreement. The assets we acquired included nine patented essential
oil bioscience products that have been developed for pain relief, cold sores,
menstrual cramps and other ailments. All of these products comply with FDA
regulations and can be sold in the United States. We are introducing these
products to the market over time. We are currently commencing to market and sell
the pain relief formulation called 024 Pain Relief. We have not yet determined
when the remaining products will be introduced. The worldwide pain management
market is estimated to be $30 billion in 2003. The combined worldwide
over-the-counter and prescription market for pain relief products is estimated
to be $15 billion in 2003

In June 2003 we entered into a transaction with Doctor's Natural Solutions Inc.,
based in Clearwater, Florida, for the purpose of acquiring Ayala, a bioscience
product that may have the potential to be used to assist in weight loss. As part
of this transaction, we provided a secured loan of $30,000 to Doctor's Natural
Solutions Inc. to continue clinical testing of Ayala. This loan was due to be
repaid in September 2003. Due to the emergence of issues that were not
contemplated in our original negotiations, we have decided that it is not in our
best interests to continue with this transaction. We will be pursuing all
options to collect the $30,000 secured loan.

We will continue to look for quality bioscience and herbal health products to
add to those we already offer. We plan to sell our products through retail
outlets, via infomercials, via the internet, through direct sales and via
multi-level marketing.



                                       7
<PAGE>


We currently have 8 individuals who render services to us for our day-to-day
operations.

We do not anticipate incurring material research and development costs during
the next 12 months, nor do we anticipate the acquisition or sale of any material
property, plant or equipment during the next 12 months, with the exception of
the possible acquisition of additional bioscience or herbal health products and
their related infrastructure.

Thus far, we have funded our operations through sales of our Common Stock and
shareholder loans. In order to support our operations and working capital
requirements through the end of 2003, we intend to raise a total of
approximately $750,000 through sales of our Common Stock and through shareholder
loans. To date, we have raised $500,000 of this amount, including $108,000 from
shareholder loans. If sales of our products will not support our operations by
the end of this period, we will attempt to raise capital through additional
sales of our securities, or through loans. We cannot assure you that we will be
successful in obtaining additional financing should it be required. If we cannot
secure adequate financing when and as needed, we may be required to cease
operations.

Through September 30, 2003 we had minimal revenue of $2,788 via sales of 024
Pain Relief over the internet, in retail stores and via direct sales. We expect
our sales to increase significantly in 2004 as we penetrate more retail
establishments and launch other channels including infomercials and internet
partnerships. As a result of increased business activity and the pursuit of our
initial acquisition, we incurred costs which have resulted in increased
operational expenses. We had a working capital deficit of $131,774 as of
September 30, 2003 and as a result of our operating losses during the nine month
period ended September 30 2003, we generated cash flow deficits of $350,662 from
operating activities.

In May 2003 we acquired nine patented bioscience products and related intangible
assets from General Cosmetics Corporation. In consideration for the acquisition
of these intangible assets, we issued a total of 6,750,000 shares of restricted
Common Stock. The stock that was issued in this transaction was valued at 85
percent of its average closing price ten days prior to and after May 21, 2003.
In accordance with Accounting Principles Board No. 29, Accounting for Non
Monetary Transactions, the cost of the intangible assets acquired is the fair
value of the Company's common stock issued of $4,532,625.

The cost to acquire the intangible assets has been preliminarily allocated to
the assets acquired according to estimated fair values and is subject to
adjustment when additional information concerning asset valuations is finalized.

In connection with the acquisition of the intangible assets, we acquired
$3,724,125 of research and development assets which were written off during the
period ended June 30, 2003 and are included in the accompanying statement of
losses as research and development expenditures.

We adopted SFAS No. 142, Goodwill and Other Intangible Assets, whereby we
periodically test our intangible assets for impairment. On an annual basis, and
when there is reason to suspect that their values have been diminished or
impaired, these assets will be tested for impairment, and write-downs to be
included in results from operations may be necessary.

Our failure to secure requisite financing when needed and on favorable terms in
the future may have a material adverse effect on our results of operations. We
have borrowed funds from principal shareholders to satisfy certain obligations.

While we have raised capital to meet our working capital and financing needs in
the past, additional financing is required in order to meet our current and
projected cash flow deficits from operations and development. We are seeking
financing in the form of equity in order to provide the necessary working
capital. We currently have no commitments for financing. There is no guarantee
that we will be successful in raising the funds required.

By adjusting our operations and development to the level of capitalization, we
believe that we have sufficient capital resources to meet projected cash flow
deficits through the end of 2003. However, if thereafter we are not successful
in generating sufficient liquidity from operations or in raising sufficient
capital resources on terms acceptable to us, our business, results of
operations, liquidity and financial condition will likely be materially
adversely effected.

The effect of inflation on our revenue and operating results was not
significant. Our operations are located in North America and there are no
seasonal aspects that would have a material effect on our financial condition or
results of operations.

During the period ended September 30, 2003 we earned minimal revenues from our
operations of $2,788. Our independent certified public accountants have stated
in their report, which is included with our audited financial statements in the
Form 10-KSB for the period ended December 31, 2002, that we have incurred
operating losses in the last two years and that we are dependent on management's
ability to develop profitable operations. These factors, among others, may raise
substantial doubt about our ability to continue as a going concern.

PART 1 - ITEM 3. DISCLOSURE CONTROLS AND PROCEDURES

         The Company carried out an evaluation, under the supervision and with
the participation of the Company's management, including the Company's Chief
Executive Officer (who is also the Company's Chief Financial Officer) of the
effectiveness of the design and operation of the Company's disclosure controls
and procedures as of the end of the period covered by this report. The
evaluation was undertaken in consultation with the Company's accounting
personnel. Based on that evaluation, the Chief Executive Officer/Chief Financial
Officer concluded that the Company's disclosure controls and procedures are
effective to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Securities Exchange Act of 1934
is recorded, processed, summarized and reported within the time periods
specified in the Securities and Exchange Commission's rules and forms.

         There were no significant changes in the Company's internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of their evaluation.



                                       8
<PAGE>


PART II

          ITEM 1.   LEGAL PROCEEDINGS

          Not applicable.

          ITEM 2.  CHANGES IN SECURITIES

During the quarter ended September 30 of 2003 we agreed to issue 272,400 shares
of our restricted Common Stock to four investors in exchange for a total
investment of $68,100 or $0.25 per share. The transaction was exempt from
registration pursuant to Regulation S of the Securities Act of 1933, inasmuch as
the offer and sales occurred outside of the United States.

During the quarter ended September 30,2003 we issued 1,240,824 shares of our
Common Stock to various individuals and corporations in exchange for management
services and consulting services. The total value of the services we received
was $252,156. These transactions were exempt from registration pursuant to
Section 4(2) of the Securities Act of 1933.

          ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

          Not Applicable

          ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

          Not Applicable.


                                       9
<PAGE>


ITEM 5.  OTHER INFORMATION

During the quarter ended September 30, 2003 we received a demand letter on
behalf of Concord Corporate Finance GmbH for services allegedly rendered to
Global Path, Inc. in its acquisition of Beta Systems AG. The letter demands that
we pay 36,384.18EURO (approximately $42,675.50) for the services. We have not
made the payment as demanded. To our knowledge, no legal action has been filed
to enforce this alleged obligation. If a legal action is filed, we intend to
vigorously defend it.

During the quarter ended September 30, 2003 we received a demand letter from
White & Case, Feddersen for the payment of legal services allegedly rendered to
Global Path, Inc. The letter demands that we pay 56,866.83EURO (approximately
$66,698) for the services. We have not made payment as demanded. To our
knowledge, no legal action has been filed to enforce this obligation. If a legal
action is filed, we intend to vigorously defend it.


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)       Exhibits

     2.1  Agreement for Purchase and Sale of Stock between Goldcrown Holdings
          Ltd. and Oxford Capital Group dated as of January 10, 2000 (1)

     2.2  Agreement for Purchase and Sale of Stock between Bodet Ltd. and Oxford
          Capital Group dated as of January 10, 2000 (1)

     2.3  Agreement and Plan of Merger of Yournet, Inc. with and into Global
          Path Incorporated dated June 25, 2001 (2)

     3.1  Articles of Incorporation, as amended (3)

     3.2  Bylaws (3)

     10.  Commitment Letter dated September 29, 2003 between the Company and
          Phillip P. MacDonald, in trust and Wolfgang H. Kyser, in trust.


     31.  Certification Pursuant to Rule 13a-14(a) and 15d-14(a)(4)

     32.  Certification Pursuant to Section 1350 of Title 18 of the United
          States Code (4)

          (1)  Incorporated by reference from a Form 8-K filed with the
               Securities and Exchange Commission on March 28, 2000.

          (2)  Incorporated by reference from a Definitive Information Statement
               filed with the Securities and Exchange Commission on July 6,
               2001.

          (3)  Previously filed.

          (4)  Filed herewith.

(b) Reports on Form 8-K

          On July 3, 2003 the registrant filed a form 8-K stating that Robert J.
          Kubbernus had resigned as a member of the Board of Directors and as an
          officer. The 8-K also stated that (i) on May 21, 2003 Reghu Kilambi
          and Grant Johnson were appointed as new directors and officers; (ii)
          on May 21, 2003, Karen Wylie was appointed Corporate Secretary, and
          (iii) on July 1, 2003, Greg Nuttall was appointed a director and
          officer.



                                       10
<PAGE>


                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                      SWISS MEDICA, INC.


                                      By: /s/ RAGHU KILAMBI
                                          ------------------------------------
Date:  November 13, 2003                  Raghu Kilambi, Chief Executive Officer
                                          and Chief Financial Officer